Physician profile
Paul C Lee
NPI 1619171428
$3,814.50
in general payments reported to CMS, 2019-2025
21 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $190 · 2021: $352 · 2022: $464 · 2023: $655 · 2024: $706 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869 · Gift: $72.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.78 |
| Gift | $72.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,887.57 | 2019-2025 | Clareon, Luxor, Ora System Verifeye |
| Carl Zeiss Meditec USA, INC. | $402.25 | 2021-2025 | Visumax |
| Rxsight INC | $276.66 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Shire North American Group INC | $170.65 | 2019 | |
| Carl Zeiss Meditec, INC. | $144.94 | 2019-2021 | |
| Sight Sciences, INC. | $111.94 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $107.26 | 2023-2024 | Tecnis Iol, Tecnis Simplicity |
| Oyster Point Pharma, INC. | $98.02 | 2022-2024 | Tyrvaya |
| Amgen INC. | $93.31 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $86.93 | 2022-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $76.03 | 2019-2020 | |
| Allergan, INC. | $72.70 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $49.16 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $39.01 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $34.53 | 2023 | Oxervate |
| Glaxosmithkline, LLC. | $34.31 | 2024 | Trelegy Ellipta |
| Bausch & Lomb Americas INC. | $31.96 | 2022-2024 | Miebo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Staar Surgical Company | $15.92 | 2019 | |
| Biotissue Holdings INC. | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.